Ignite Creation Date:
2024-05-06 @ 5:56 PM
Last Modification Date:
2024-10-26 @ 2:38 PM
Study NCT ID:
NCT05488561
Status:
UNKNOWN
Last Update Posted:
2022-08-04
First Post:
2022-08-03
Brief Title:
Clinical and Molecular Evaluation of Childern With Familial Meditterranean Fever and Their Siblings
Sponsor:
Sohag University
Organization:
Sohag University
Study Overview
Official Title:
Clinical and Molecular Evaluation of Childern With Familial Meditterranean Fever and Their Siblings
Status:
UNKNOWN
Status Verified Date:
2022-08
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Familial Mediterranean fever FMF recurrent polyserositis periodic disease is an autosomal recessive auto inflammatory disease which primarily affect population surrounding the Mediterranean basin Arabs Turks Armenians Jews Despite its striking symptoms pattern FMF was first described as distinct entity only in 1945
It is characterized by recurrent attacks of fever peritonitis pleurisy arthritis or erysipelas like skin disease The most dangerous complication of this disease is secondary amyloidosis FMF diagnosis is mainly clinical and the genetic testing is indicated to support it Uncommonly amyloidosis may develop in individuals carrying two Familial Mediterranean fever gene MEFV mutations without overt clinical symptoms of FMF a condition designated as phenotype II Furthermore two MEFV mutations may be harbored without signs or symptoms of FMF nor of reactive amyloidosis This silent homozygous or compound heterozygote state is termed phenotype III
It is characterized by recurrent attacks of fever peritonitis pleurisy arthritis or erysipelas like skin disease The most dangerous complication of this disease is secondary amyloidosis FMF diagnosis is mainly clinical and the genetic testing is indicated to support it Uncommonly amyloidosis may develop in individuals carrying two Familial Mediterranean fever gene MEFV mutations without overt clinical symptoms of FMF a condition designated as phenotype II Furthermore two MEFV mutations may be harbored without signs or symptoms of FMF nor of reactive amyloidosis This silent homozygous or compound heterozygote state is termed phenotype III
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None